Some patients with giant cell arteritis (GCA) maintain remission up to a year after discontinuation of tocilizumab therapy, according to long-term results from the GiACTA trial. Part one of the trial showed that tocilizumab plus blinded prednisone taper was more effective than placebo plus prednisone taper for inducing a sustained remission. “However, the duration of ...
Some GCA remissions persist long-term after tocilizumab discontinuation: study
By Dave Levitan
25 Mar 2021